Despite losing patent protection for its blockbuster drug, Singulair, over the summer, pharma giant Merck's (NYSE: MRK) shares have appreciated 18% year to date, and the company has a slew of therapeutics in development. In addition, while some of the biggest players in the health care space -- including Pfizer (NYSE: PFE) and Abbott (NYSE: ABT) -- are spinning-out businesses, Merck doesn't look like it will be following suit.
In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Merck's current strategy and give a helpful overview of the company's main growth drivers.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.